Drug Development

Articles

ADC Biotechnology will invest downstream formulation, fill/finish capabilities, and Lock-Release conjugation technology.

ADC Bio Secures Additional Equity Round Investment

The testing of raw materials is essential as raw material quality determines the outcome of biologic product quality.

Analytical Best Practices for Raw Materials Testing

The new program will provide cell and gene therapy companies a more efficient way to ensure quality compliance across collection center networks and to minimize quality system audit burden on these centers.

Be The Match BioTherapies Launches Program for Faster Cell Facility Onboarding

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Demand for highly potent APIs continues to rise.

Building Capacity for Potent API Production

The companies announced the European launch of Imraldi (adalimumab), a biosimilar referencing AbbVie’s blockbuster Humira (adalimumab).

Biogen and Samsung Bioepis Launch Humira Biosimilar in Europe

Mylan announced the launch of its biosimilar to AbbVie’s Humira across major European markets.

Mylan Launches Humira Biosimilar in Europe

An advanced combination polymer for enteric coatings has been launched by Evonik and will be showcased during AAPS PharmSci 360 in Washington D.C.

Evonik Launches Advanced Combination Polymer for Enteric Coatings

Cambrex will create a new center of excellence for API process development and clinical supply at its High Point, NC facility and expand its API manufacturing facility in Italy. 

Cambrex Development Center in North Carolina Focuses on Continuous Flow

Clovis Oncology and Lonza celebrated the grand opening of a dedicated production train at Lonza’s Visp, Switzerland site for manufacturing Rubraca (rucaparib).

Lonza Opens Monoplant for Clovis Oncology’s Rubraca

The company’s planned investment in its alkoxylation facility in the United States Gulf Coast will also expand production capacity for its polyethylene glycols.

APIs and Excipients